Dyne Therapeutics Inc. | Small-cap | Healthcare
$8.18
-6.62%
| Dyne Therapeutics Stock Comparison:
Dyne Therapeutics vs VertexDyne Therapeutics vs RegeneronDyne Therapeutics vs Vera TherapeuticsDyne Therapeutics vs Immunocore HoldingsDyne Therapeutics vs AgiosDyne Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -343.9M
Net Income -317.4M

Balance Sheet Metrics

Total Assets 691.2M
Total Liabilities 61.4M
Shareholders Equity 629.8M
Debt to Equity 0.10

Cash Flow Metrics

Operating Cash Flow -278.3M
Free Cash Flow -294.7M

Revenue & Profitability Trend

Dyne Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue00000
Cost of Goods Sold-----
Gross Profit-----
Operating Expenses343.9M242.2M171.0M150.0M58.6M
Operating Income-343.9M-242.2M-171.0M-150.0M-58.6M
Pre-tax Income-317.4M-235.9M-168.1M-149.3M-59.4M
Income Tax-----
Net Income-317.4M-235.9M-168.1M-149.3M-59.4M
EPS (Diluted)--$3.95-$3.23-$2.93-$4.13

Income Statement Trend

Dyne Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets659.3M129.4M265.6M382.4M349.1M
Non-Current Assets32.0M35.7M40.7M43.3M4.2M
Total Assets691.2M165.1M306.3M425.7M353.3M
Liabilities
Current Liabilities42.3M51.1M28.1M28.7M11.0M
Non-Current Liabilities19.1M22.7M25.9M28.7M0
Total Liabilities61.4M73.8M54.0M57.5M11.0M
Equity
Total Shareholders Equity629.8M91.3M252.4M368.2M342.4M

Balance Sheet Composition

Dyne Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-317.4M-235.9M-168.1M-149.3M-59.4M
Operating Cash Flow-278.3M-190.5M-150.8M-120.6M-43.1M
Investing Activities
Capital Expenditures-2.4M-729.0K-3.1M-3.6M-1.2M
Investing Cash Flow-204.1M83.3M87.2M-137.9M-90.2M
Financing Activities
Dividends Paid-----
Financing Cash Flow773.1M52.4M36.9M157.2M380.7M
Free Cash Flow-294.7M-188.9M-156.7M-123.2M-47.7M

Cash Flow Trend

Dyne Therapeutics Key Financial Ratios

Valuation Ratios

Forward P/E -3.22
Price to Book 1.73
PEG Ratio -3.22

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -64.01%
Return on Assets -39.92%

Financial Health

Current Ratio 20.35
Debt to Equity 3.49
Beta 1.16

Per Share Data

EPS (TTM) -$3.61
Book Value per Share $5.89

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
dyn1.2B-1.73-64.01%0.00%3.49
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Vera Therapeutics 1.4B-8.412.58-39.49%0.00%10.18
Immunocore Holdings 1.6B-31.414.13-5.86%-6.48%114.67
Agios 1.9B2.891.3260.26%1,798.26%3.61

Financial data is updated regularly. All figures are in the company's reporting currency.